Treatment of CO2 laser induced hypopigmentation with ablative fractionated laser resurfacing: case report and review of the literature.

The carbon dioxide laser (CO2) has been proven to be an effective device for the treatment of photoaging. However, it is associated with adverse side effects including prolonged erythema, edema, burning, milia, acne, crusting and hypo-/hyperpigmentation. Delayed onset hypopigmentation after CO, laser resurfacing can markedly detract from clinical outcomes. To overcome the disadvantages of traditional ablative and non-ablative resurfacing, fractional photothermolysis (FP) has been introduced. FP has been demonstrated in early case reports and case series to produce significant improvement in hypopigmentation of acne and surgical scars.
A 53-year-old Caucasian female with Fitzpatrick type I skin presented with a nine-month history of delayed onset hypopigmentation following ablative CO2 laser resurfacing. After a series of three treatments at eight-week intervals with an ablative fractionated CO2 laser device, the hypopigmentation and line of pigmentary demarcation between the face and neck improved by 75 percent.
Ablative fractional resurfacing is a safe and potentially effective modality for the treatment of CO2 laser induced hypopigmentation on the face.
AuthorsEmily P Tierney, C William Hanke
JournalJournal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 9 Issue 11 Pg. 1420-6 (Nov 2010) ISSN: 1545-9616 [Print] United States
PMID21061766 (Publication Type: Case Reports, Journal Article, Review)
  • Face
  • Female
  • Humans
  • Hypopigmentation (etiology, surgery)
  • Laser Therapy (adverse effects)
  • Lasers, Gas (adverse effects)
  • Middle Aged
  • Skin Aging

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: